Status:
RECRUITING
Revisiting the Universal Donor: Does Exposure to O Blood Products Affect Patient Outcomes?
Lead Sponsor:
McMaster University
Collaborating Sponsors:
CBS
Conditions:
Myelodysplastic Syndrome
Eligibility:
All Genders
18-120 years
Phase:
NA
Brief Summary
In a recent analysis of a large transfusion database (Transfusion Research Utilization, Surveillance and Tracking database \[TRUST\]), the investigators found that the transfusion of ABO non-identical...
Detailed Description
Why ABO non-identical RBCs may cause harm: In addition to the two exploratory studies published by our group (Z. Sohl, personal communication, April 30th, 2020), other investigators have also suggeste...
Eligibility Criteria
Inclusion
- Age ≥ 18 years of age
- Diagnosis of MDS (Myelodysplastic syndrome ) without leukemia (IPSS-R classified or physician indicated either low-risk or intermediate-1)
- Stable disease (as assessed by the patient's physician using MDS Stability Assessment Algorithm)
- Blood group A, B, or AB
- Requiring 2 RBC units at least every 6 weeks or less
- Receiving transfusions in an outpatient setting
Exclusion
- Unable to provide informed consent
- Blood group O
- Clinical requirement for special products because of reactions (e.g. washed or volume-reduced)
Key Trial Info
Start Date :
October 17 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04859218
Start Date
October 17 2023
End Date
December 1 2025
Last Update
October 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Juravinski Hospital and Cancer Centre
Hamilton, Ontario, Canada, L8V-1C3